PRKCB and B-cell chronic lymphocytic leukemia: In addition to prkcb downregulation, mtm treatment reduces expression of blnk, bcl2, vegfa, lef1 and sp1 in the PKCα-KR-transduced cells, and mtm treatment of CLL cells results in comparable downregulation of the human orthologues of these genes.